株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

血液診断の世界市場:将来の展望と予測

Global Hematology Diagnostics Market Outlook and Projections, 2019-2027

発行 Research Nester 商品コード 920991
出版日 ページ情報 英文 189 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.80円で換算しております。
Back to Top
血液診断の世界市場:将来の展望と予測 Global Hematology Diagnostics Market Outlook and Projections, 2019-2027
出版日: 2019年12月19日 ページ情報: 英文 189 Pages
概要

当レポートでは、世界の血液市場の将来展望について分析し、市場の基本構造や最新情勢、技術開発の動きと開発・普及の動き、全体的な市場規模の動向見通し (通算10年間分)、製品別・携帯性別・用途別・エンドユーザー別および地域別・国別の詳細動向、主な市場促進・抑制要因、主要企業のプロファイル、といった情報を取りまとめてお届けいたします。

第1章 イントロダクション

第2章 前提条件、略語一覧

第3章 分析手法

  • 変数 (独立・従属変数)
  • 多要素ベース感度モデル

第4章 エグゼクティブサマリー - 世界の血液診断市場

第5章 主な市場機会

第6章 規制環境

第7章 デバイスの一覧

  • 血液診断
  • コンパニオン診断

第8章 コンパニオン診断の活用分野 (概要):薬力学/薬物動態額の場合

第9章 市場のダイナミクスの分析

  • 市場促進要因
  • 市場抑制要因
  • 市場動向

第10章 市場リスクの分析

  • 需要リスクの分析
  • 供給リスクの分析

第11章 世界の血液診断市場の将来展望

  • 市場規模とその予測 (金額ベース、通算10年間分)
  • 市場規模とその予測:分野別 (金額ベース、通算10年間分)
    • 製品別:試薬、診断・分析装置、ソフトウェア・サービス
    • 携帯性別:POC (ポイントオブケア) 装置、スタンドアロン式装置
    • 用途別
      • 腫瘍、マラリア、全血球計算、血小板機能、その他 (HIV、糖尿病、遺伝性難治疾患)
      • 貧血 (鎌状赤血球欠乏症、サラセミア)、その他 (ビタミン欠乏性貧血、鉄欠乏性貧血など))
    • エンドユーザー別:病院、診断検査室、日帰り手術センター (ASC)、クリニック、その他 (教育・研究機関など)

第12章 北米の血液診断市場の将来展望

  • 市場規模とその予測 (金額ベース、通算10年間分)
  • マクロ経済指標:国別
  • 市場規模とその予測:分野別 (通算10年間分)
    • 製品別
    • 携帯性別
    • 用途別
    • エンドユーザー別
    • 国別 (米国、カナダ)

第13章 欧州の血液診断市場の将来展望

  • 市場規模とその予測:分野別 (通算10年間分)
    • 国別 (英国、ドイツ、フランス、イタリア、ロシア、スペインなど)

第14章 アジア太平洋地域の血液診断市場の将来展望

  • 市場規模とその予測:分野別 (通算10年間分)
    • 国別 (中国、インド、日本、マレーシア、韓国、オーストラリアなど)

第15章 ラテンアメリカの血液診断市場の将来展望

  • 市場規模とその予測:分野別 (通算10年間分)
    • 国別 (メキシコ、ブラジルなど)

第16章 中東・アフリカの血液診断市場の将来展望

  • 市場規模とその予測:分野別 (通算10年間分)
    • 国別 (イスラエル、南アフリカ、サウジアラビア、UAEなど)

第17章 企業構造

  • 概要
  • 主要製品/サービスの評価
  • 成長戦略の分析
  • 主な財務指標:包括的分析
  • 地域別の市場プレゼンス
  • 主な事業提携先と協力関係
  • 近年の動向
  • 企業プロファイル
    • ABBOTT
    • シスメックス
    • BECKMAN COULTER, INC.
    • SIEMENS HEALTHCARE GMBH
    • BOULE DIAGNOSTICS AB
    • F. HOFFMANN-LA ROCHE LTD
    • SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • BIO-RAD LABORATORIES, INC.
    • CELLAVISION
    • その他の企業

第18章 戦略提言

目次

The global hematology diagnostics market reached USD 4,702.88 million in 2018 and is expected to reach USD 7,989.73 million by 2027, by registering a CAGR of 6.06%, across the globe. This is primarily attributed to the growing demand for advanced diagnostics across the world.

North America had a market share of 37.94% in the year 2018 and is expected to dominate the market, over the forecast period. The growth in the region can be attributed to increase in investments towards healthcare from government and private entities to maintain the highest quality of care offered in healthcare facilities. The US is the major country driving the growth in the region, reaching a market value of USD 1,567.36 million in 2018 and is expected to grow at a CAGR of 6.23% over the forecast period i.e. 2020-2027. On the back of rising adoption of innovative diagnostic methods focused on minimally in-vitro diagnostics, the market is expected to grow over the forecast period.

The Asia Pacific region captured a market size of USD 1,002.46 million in the year 2018 and is expected to reach USD 1,820.23 million by 2027, with a CAGR of 6.85%. The market is primarily led by the demand from China, with a market of USD 367.57 million in the year 2018, and it is expected to grow at a CAGR of 7.75%. With the rising availability of advanced healthcare in this region along with rising number of manufacturers investing in countries such as China, Japan, & India to address the growing demand for advanced diagnostics in this region, the demand for hematology diagnostics products in this region is expected to witness a rapid growth over the forecast period.

Europe is expected to reach a market size of USD 2,114.07 million by 2027. It has been observed that with the availability of innovative treatment modalities, there has been a rise in demand for effective diagnostic products in the region for time sensitive diagnosis. Primarily driven by the demand from Germany, UK, France & Italy, this region is expected to showcase a high demand over the forecast period.

In comparison, the Latin America and Middle East & Africa region is presently generating a moderate demand for the hematology diagnostics products. It has been observed that there are a high number of patients, who opt for various medical procedures, travelling to other geographies with adequate healthcare resources. While this boosts the medical tourism in the travelled country, it points out the wide gap in the availability of health resources in these regions. However, with gradually rising disposable income, encouraging government regulatory policies, and a potential interest of global manufacturers to have a direct market presence in this region, it is expected that the market for hematology diagnostics in these regions would grow over the forecast period.

1. INTRODUCTION

  • 1.1. MARKET DEFINITION
  • 1.2. MARKET SEGMENTATION
  • 1.3. PRODUCT OVERVIEW

2. ASSUMPTIONS AND ACRONYMS

3. RESEARCH METHODOLOGY

  • 3.1. VARIABLES (DEPENDENT AND INDEPENDENT)
  • 3.2. MULTI FACTOR BASED SENSITIVITY MODEL

4. EXECUTIVE SUMMARY - GLOBAL HEMATOLOGY DIAGNOSTICS MARKET

5. KEY MARKET OPPORTUNITIES

6. REGULATORY LANDSCAPE

7. LIST OF DEVICES

  • 7.1. HEMATOLOGY DIAGNOSTICS
  • 7.2. COMPANION DIAGNOSTICS

8. OVERVIEW OF APPLICATIONS OF COMPANION DIAGNOSTICS IN PHARMACODYNAMICS/PHARMACOKINETICS

9. ANALYSIS OF MARKET DYNAMICS

  • 9.1. DRIVERS
  • 9.2. RESTRAINTS
  • 9.3. TRENDS

10. MARKET RISK ANALYSIS

  • 10.1. DEMAND RISK ANALYSIS
  • 10.2. SUPPLY RISK ANALYSIS

11. GLOBAL HEMATOLOGY DIAGNOSTICS MARKET OUTLOOK

  • 11.1. MARKET SIZE AND FORECAST, 2018-2027
    • 11.1.1. BY VALUE (USD MILLION)
  • 11.2. GLOBAL HEMATOLOGY DIAGNOSTICS MARKET SEGMENTATION, 2018-2027
    • 11.2.1. BY PRODUCT

REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

    • 11.2.2. BY PORTABILITY

POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

    • 11.2.3. BY APPLICATIONS

ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

    • 11.2.4. BY END USER

HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

12. NORTH AMERICA HEMATOLOGY DIAGNOSTICS MARKET OUTLOOK

  • 12.1. MARKET SIZE AND FORECAST, 2018-2027
    • 12.1.1. BY VALUE (USD MILLION)
  • 12.2. MACROECONOMIC INDICATORS, BY COUNTRY
  • 12.3. NORTH AMERICA HEMATOLOGY DIAGNOSTICS MARKET SEGMENTATION, 2018-2027
    • 12.3.1. BY PRODUCT

REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

    • 12.3.2. BY PORTABILITY

POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

    • 12.3.3. BY APPLICATIONS

ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

    • 12.3.4. BY END USER

HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

    • 12.3.5. BY COUNTRY

US AND CANADA, 2018-2027F (USD MILLION)

13. EUROPE HEMATOLOGY DIAGNOSTICS MARKET OUTLOOK

  • 13.1. MARKET SIZE AND FORECAST, 2018-2027
    • 13.1.1. BY VALUE (USD MILLION)
  • 13.2. MACROECONOMIC INDICATORS, BY COUNTRY
  • 13.3. EUROPE HEMATOLOGY DIAGNOSTICS MARKET SEGMENTATION, 2018-2027
    • 13.3.1. BY PRODUCT

REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

    • 13.3.2. BY PORTABILITY

POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

    • 13.3.3. BY APPLICATIONS

ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

    • 13.3.4. BY END USER

HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

    • 13.3.5. BY COUNTRY

UK, GERMANY, FRANCE, ITALY, RUSSIA, SPAIN, AND REST OF EUROPE, 2018-2027F (USD MILLION)

14. ASIA PACIFIC HEMATOLOGY DIAGNOSTICS MARKET OUTLOOK

  • 14.1. MARKET SIZE AND FORECAST, 2018-2027
    • 14.1.1. BY VALUE (USD MILLION)
  • 14.2. MACROECONOMIC INDICATORS, BY COUNTRY
  • 14.3. ASIA PACIFIC HEMATOLOGY DIAGNOSTICS MARKET SEGMENTATION, 2018-2027
    • 14.3.1. BY PRODUCT

REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

    • 14.3.2. BY PORTABILITY

POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

    • 14.3.3. BY APPLICATIONS

ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

    • 14.3.4. BY END USER

HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

    • 14.3.5. BY COUNTRY

CHINA, INDIA, JAPAN, MALAYSIA, SOUTH KOREA, AUSTRALIA, AND REST OF ASIA PACIFIC, 2018-2027F (USD MILLION)

15. LATIN AMERICA HEMATOLOGY DIAGNOSTICS MARKET OUTLOOK

  • 15.1. MARKET SIZE AND FORECAST, 2018-2027
    • 15.1.1. BY VALUE (USD MILLION)
  • 15.2. MACROECONOMIC INDICATORS, BY COUNTRY
  • 15.3. LATIN AMERICA HEMATOLOGY DIAGNOSTICS MARKET SEGMENTATION, 2018-2027
    • 15.3.1. BY PRODUCT

REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

    • 15.3.2. BY PORTABILITY

POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

    • 15.3.3. BY APPLICATIONS

ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

    • 15.3.4. BY END USER

HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

    • 15.3.5. BY COUNTRY

MEXICO, BRAZIL AND REST OF LATIN AMERICA, 2018-2027F (USD MILLION)

16. MIDDLE EAST & AFRICA HEMATOLOGY DIAGNOSTICS MARKET OUTLOOK

  • 16.1. MARKET SIZE AND FORECAST, 2018-2027
    • 16.1.1. BY VALUE (USD MILLION)
  • 16.2. MACROECONOMIC INDICATORS, BY COUNTRY
  • 16.3. MIDDLE EAST & AFRICA HEMATOLOGY DIAGNOSTICS MARKET SEGMENTATION, 2018-2027
    • 16.3.1. BY PRODUCT

REAGENTS, INSTRUMENTS & ANALYZERS AND SOFTWARE & SERVICES, 2018-2027F (USD MILLION)

    • 16.3.2. BY PORTABILITY

POINT-OF-CARE (POC) DEVICES AND STANDALONE, 2018-2027F (USD MILLION)

    • 16.3.3. BY APPLICATIONS

ONCOLOGY, MALARIA, ANEMIA, BOOD COUNT, PLATELET FUNCTION, AND OTHERS (HIV, DIABETES, RARE GENETIC DISORDERS), 2018-2027F (USD MILLION)

ANEMIA: SICKLE CELL ANEMIA, THALASSEMIA AND OTHERS (VITAMIN DEFICIENCY ANEMIA, IRON DEFICIENCY ANEMIA), 2018-2027F (USD MILLION)

    • 16.3.4. BY END USER

HOSPITALS, DIAGNOSTIC LABS, AMBULATORY SURGICAL CENTERS, CLINICS AND OTHERS (RESEARCH & EDUCATIONAL INSTITUTES), 2018-2027F (USD MILLION)

    • 16.3.5. BY COUNTRY

ISRAEL, SOUTH AFRICA, SAUDI ARABIA, UAE, AND REST OF MIDDLE EAST & AFRICA, 2018-2027F (USD MILLION)

17. COMPETITIVE STRUCTURE

  • 17.1. DETAILED OVERVIEW
  • 17.2. ASSESSMENT OF KEY PRODUCT OFFERINGS
  • 17.3. ANALYSIS OF GROWTH STRATEGIES
  • 17.4. EXHAUSTIVE ANALYSIS ON KEY FINACIAL INDICATORS
  • 17.5. REGIONAL PRESENCE
  • 17.6. KEY PARTNERS AND COLLABORATIONS
  • 17.7. RECENT NEWS AND DEVELOPMENTS
  • 17.8. COMPANY PROFILES

ABBOTT

SYSMEX

BECKMAN COULTER, INC.

SIEMENS HEALTHCARE GMBH

BOULE DIAGNOSTICS AB

F. HOFFMANN-LA ROCHE LTD

SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

BIO-RAD LABORATORIES, INC.

CELLAVISION

OTHER PROMINENT PLAYERS

18. STRATEGIC RECOMMENDATIONS

Back to Top